Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Feedback flags fast-growing demand in Asia

Joint marketing and promotional activities in South Korea and China have been well-received
Medical scan
Feedback continues to receive significant TexRAD research interest from prestigious institutions worldwide

Specialist medical imaging technology company Feedback plc (LON:FDBK) said it is receiving significant interest in China for its TexRAD product.

In its full-year results statement it also mentioned it has seen an increase in purchase orders for TexRAD from leading medical institutions in South Korea; the company signed exclusive distributor agreements in the middle of the year covering South Korea and China.

READ: Feedback announces exclusive distribution agreement with China's Boya Digital Technology

Revenue for the year to the end of May rose to £465,885 from £431,454.

The loss before tax widened to £300,927 from £251,219 the previous year, reflecting an increase in operating expenses to £755,960 from £676,596.

The company ended the reporting period with cash and cash equivalents of £696,811, up from £105,673 a year earlier.

“Our technical and regulatory team have been working diligently on the delivery of a CE marked release of TexRAD Lung," said Dr Alastair Riddell, chairman of Feedback.

READ: Feedback PLC's eye on the prize: a CE mark for TexRAD

“We are acutely aware that this development has taken longer than originally expected; however, we are confident that our rigorous regulatory review will pave the way for new products and therefore maximise the potential for TexRAD's clinical use worldwide,” he continued.

“We remain focused on applying our leading research expertise to the clinical setting to drive future revenue growth and would like to thank our shareholders, customers and partners for their continued support."

View full FDBK profile View Profile

Feedback plc Timeline

Related Articles

ITM Power's first hydrogen station in London
July 11 2017
Electricity to hydrogen conversion technology has the potential to revolutionise the way we store renewable energy.
LED lighting
March 20 2017
Whilst the commercial launch of halcyon is imminent, set for April 1, the AIM-listed firm has already been rolling-out the product via paid-for technology trials
Medical Scan
May 18 2017
The CE mark will enable Feedback to market not just to scientists, but radiologists everywhere, which should lead to a marked expansion in sales

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use